DBV Technologies | DBVT - Assets


DBV Technologies reported $110.49M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.56B 233.42M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amarin USD 659.81M 10.31M Sep/2025
BioCryst Pharmaceuticals USD 514.16M 67.73M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
DBV Technologies USD 110.49M 32.93M Sep/2025
Esperion Therapeutics USD 465.89M 101.87M Dec/2025
Galectin Therapeutics USD 27.65M 1.76M Jun/2024
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
Insmed USD 2.26B 96.18M Dec/2025
Ionis Pharmaceuticals USD 3.52B 490.91M Dec/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
United Therapeutics USD 7.88B 528.9M Dec/2025